Table 1.
Significant associations found between CCLE, GDSC, GSK and GCSI.
| CCLE vs GDSC | CCLE vs GDSC | CCLE vs GSK | ||||||
|---|---|---|---|---|---|---|---|---|
| IC50 | AUC | IC50 | ||||||
| Drug | Cluster | Response | Drug | Cluster | Response | Drug | Cluster | Response |
| Erlotinib | ADG | Sensitive | Erlotinib | ADG | Sensitive | Lapatinib | Mixed 1 | Resistant |
| AZD6244 | SKCM | Sensitive | AZD6244 | SKCM | Sensitive | Lapatinib | SKCM | Resistant |
| AZD6244 | BRCA | Resistant | AZD6244 | BRCA | Resistant | |||
| Lapatinib | SCLC | Resistant | Lapatinib | HAL | Resistant | |||
| Lapatinib | ADG | Sensitive | Crizotinib | SKCM | Resistant | |||
| PD0332991 | GI | Resistant | AZD0530 | SKCM | Resistant | |||
| PD0332991 | HAL | Sensitive | PLX4720 | SKCM | Sensitive | |||
| PLX4720 | SKCM | Sensitive | ||||||
| PD0325901 | GI | Sensitive | ||||||
| PD0325901 | SKCM | Sensitive | ||||||
| CCLE vs gCSI | GDSC vs gCSI | |||||||
| IC50 | IC50 | |||||||
| Drug | Cluster | Response | Drug | Cluster | Response | |||
| Erlotinib | ADG | Sensitive | PD0325901 | SKCM | Sensitive* | |||
| Erlotinib | Mixed 1 | Resistant | ||||||
| Erlotinib | GLSR | Resistant | ||||||
| Erlotinib | SKCM | Resistant | ||||||
| Lapatinib | Mixed 1 | Resistant | ||||||
| Lapatinib | ADG | Sensitive | ||||||
| PD0325901 | BRCA | Resistant | ||||||
| PD0325901 | SKCM | Sensitive | ||||||
| CCLE vs gCSI | GDSC vs gCSI | |||||||
| Mean Viability | Mean Viability | |||||||
| Drug | Cluster | Response | Drug | Cluster | Response | |||
| Erlotinib | ADG | Sensitive | PD0325901 | SKCM | Sensitive | |||
| Erlotinib | Mixed 1 | Resistant | ||||||
| Erlotinib | GLSR | Resistant | ||||||
| Erlotinib | SKCM | Resistant | ||||||
| Erlotinib | HAL | Resistant | ||||||
| Erlotinib | SCLC | Resistant | ||||||
| PD0325901 | BRCA | Resistant | ||||||
| PD0325901 | SKCM | Sensitive | ||||||
In bold associations found significant in at least three datasets. The association between PD0325901 and SKCM had an adjusted p-values of 0.058 (marked with*).